A Phase II Study of Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL).
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2012
At a glance
- Drugs Alemtuzumab; Cyclophosphamide; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 01 Mar 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 22 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Mar 2010 New trial record